Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -98.17% is in line with its 5-year average of -94.26%, around the middle of its 5-year range (-191.62%–-28.05%).
36.58% above its 12-month average of -154.79%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.77%.
RETURN ON ASSETS (ROA)
-98.17%
RETURN ON ASSETS (ROA) AVG TTM
-154.79%
RETURN ON ASSETS (ROA) AVG 3Y
-120.06%
RETURN ON ASSETS (ROA) AVG 5Y
-94.26%
RETURN ON ASSETS (ROA) AVG 10Y
-72.29%
RETURN ON ASSETS (ROA) AVG 15Y
-59.70%
RETURN ON ASSETS (ROA) AVG 20Y
-60.16%
CURRENT VS TTM AVG
+36.58%
CURRENT VS 3Y AVG
+18.23%
CURRENT VS 5Y AVG
-4.15%
CURRENT VS 10Y AVG
-35.80%
CURRENT VS 15Y AVG
-64.45%
CURRENT VS 20Y AVG
-63.20%
SECTOR MEDIAN · HEALTHCARE
-30.07%
median of 666 covered companies
CURRENT VS SECTOR MEDIAN
-226.47%
vs the sector median at left
Imunon, Inc.
Market Cap
$5.11M
Return on Assets (ROA)
-98.17%
TTM Avg
-154.79%
3Y Avg
-120.06%
5Y Avg
-94.26%
Market Cap
$5.34M
Return on Assets (ROA)
-1300.98%
TTM Avg
-1108.45%
3Y Avg
-604.75%
5Y Avg
-486.62%
Market Cap
$4.98M
Return on Assets (ROA)
-108.91%
TTM Avg
-143.36%
3Y Avg
-200.57%
5Y Avg
-146.87%
Market Cap
$5.23M
Return on Assets (ROA)
-367.93%
TTM Avg
-1046.51%
3Y Avg
-534.79%
5Y Avg
-427.52%
Market Cap
$5.27M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$5.01M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
Market Cap
$5.29M
Return on Assets (ROA)
-106.49%
TTM Avg
-259.99%
3Y Avg
-586.63%
5Y Avg
-434.16%
Market Cap
$5.32M
Return on Assets (ROA)
-30.94%
TTM Avg
-24.01%
3Y Avg
-19.50%
5Y Avg
-23.56%
Market Cap
$4.86M
Return on Assets (ROA)
-161.71%
TTM Avg
-175.21%
3Y Avg
-164.83%
5Y Avg
-138.13%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Imunon, Inc. (IMNN) | $5.11M | -98.17% | -154.79% | -120.06% | -94.26% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.34M | -1300.98% | -1108.45% | -604.75% | -486.62% |
| CalciMedica, Inc. (CALC)vs › | $4.98M | -108.91% | -143.36% | -200.57% | -146.87% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.23M | -367.93% | -1046.51% | -534.79% | -427.52% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | -104.10% | -116.11% | -102.15% | -84.67% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -71.72% | -29.50% | -8.92% | -8.92% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -106.49% | -259.99% | -586.63% | -434.16% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -30.94% | -24.01% | -19.50% | -23.56% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.86M | -161.71% | -175.21% | -164.83% | -138.13% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.68M | -28.02% | -155.25% | -160.56% | -117.99% |
ROA
-98.2%
ROE
-351.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -117.96% |
| 2024-12-31 | -191.62% |
| 2023-12-31 | -89.04% |
| 2022-12-31 | -81.63% |
| 2021-12-31 | -28.05% |
| 2020-12-31 | -57.25% |
| 2019-12-31 | -44.02% |
| 2018-12-31 | -25.36% |
| 2017-12-31 | -42.94% |
| 2016-12-31 | -71.49% |
| 2015-12-31 | -45.81% |
| 2014-12-31 | -38.23% |
| 2013-12-31 | -18.07% |
| 2012-12-31 | -104.77% |
| 2011-12-31 | -71.13% |
| 2010-12-31 | -745.21% |
| 2009-12-31 | -102.62% |
| 2008-12-31 | -49.76% |
| 2007-12-31 | 90.55% |
| 2006-12-31 | -40.07% |
| 2005-12-31 | -54.59% |
| 2004-12-31 | -82.01% |
| 2003-09-30 | -91.93% |
| 2002-09-30 | -425.54% |
| 2001-09-30 | -234.14% |
| 2000-09-30 | -49.87% |
| 1999-09-30 | -150.00% |
| 1998-09-30 | -1270.03% |
| 1997-09-30 | -370.73% |
| 1996-09-30 | -20.74% |
